Nampt-IN-3

Overview

Nampt-IN-3 (Compound 35) simultaneously inhibit nicotinamide phosphoribosyltransferase ( NAMPT ) and HDAC with IC 50 s of 31 nM and 55 nM, respectively. Nampt-IN-3 effectively induces cell apoptosis and autophagy and ultimately leads to cell death.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > NAMPT | Products > Signaling Pathways > HDAC | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-108701
• CAS No.: 2121591-52-2
• Molecular Formula: C29H25N7O2
• Molecular Weight: 503.55
• Purity: 98.97%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source